U.S. markets closed
  • S&P Futures

    4,376.75
    -35.00 (-0.79%)
     
  • Dow Futures

    34,853.00
    -121.00 (-0.35%)
     
  • Nasdaq Futures

    14,828.50
    -209.25 (-1.39%)
     
  • Russell 2000 Futures

    2,221.50
    -16.00 (-0.72%)
     
  • Crude Oil

    73.26
    -0.36 (-0.49%)
     
  • Gold

    1,831.70
    -4.10 (-0.22%)
     
  • Silver

    25.55
    -0.24 (-0.92%)
     
  • EUR/USD

    1.1888
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.2690
    +0.0080 (+0.63%)
     
  • Vix

    17.70
    -0.61 (-3.33%)
     
  • GBP/USD

    1.3951
    -0.0007 (-0.05%)
     
  • USD/JPY

    109.5300
    +0.0690 (+0.06%)
     
  • BTC-USD

    39,892.38
    +312.08 (+0.79%)
     
  • CMC Crypto 200

    946.72
    +16.36 (+1.76%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,503.60
    -278.82 (-1.00%)
     
  • Oops!
    Something went wrong.
    Please try again later.

Nvidia Slips As Report Says Arm Buyout May Take Time

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Dhirendra Tripathi

Investing.com – Nvidia (NASDAQ:NVDA) shares fell Tuesday following a report in Financial Times that the chipmaker may exceed the 18-month timeline it set last September to complete the $40 billion takeover of the U.K. chip designer Arm.

According to the FT report, Nvidia has submitted an application to Chinese competition regulators in recent weeks and it sets in motion a period of scrutiny that could itself take up to 18 months, breaching Nvidia’s targeted deadline.

Arm has as a joint venture, headquartered in Shanghai, with Chinese private equity firm Hopu Investments. Nvidia will need the approval of the authorities there to acquire a stake in Arm China.

Huawei’s HiSilicon and Semiconductor Manufacturing International Corporation, as well as state-backed chip investment group E-Town Capital have opposed the Nvidia-Arm deal, FT said.

 

Related Articles

Nvidia Slips As Report Says Arm Buyout May Take Time

Pfizer to test COVID-19 vaccine in larger group of children below 12

Biogen to start shipping Alzheimer's drug in about two weeks